As proteomics research advances, researchers are increasingly confronted with larger sample sizes, particularly in application scenarios such as integrated multi-omics analysis, disease cohort studies, and drug screening. This has driven a growing demand for quantitative techniques that combine high throughput with high accuracy. Among the available strategies, tandem mass tag (TMT)–based quantification has emerged as one of the most widely adopted approaches in quantitative proteomics, owing to its exceptional multiplexing capability (supporting up to 18-plex parallel sample analysis), high reproducibility, and relatively low inter-batch variation. Current mainstream TMT quantification platforms each offer distinct advantages. For instance, the Orbitrap Eclipse delivers ultra-high resolution and superior scan rates, making it well-suited for in-depth characterization of highly complex samples, while the Exploris 480 provides stable performance for high-throughput screening applications. Selecting the most appropriate TMT platform often requires careful consideration of technical specifications, application needs, and budget constraints. This review provides a systematic overview of the performance characteristics of mainstream TMT platforms, key factors influencing quantitative outcomes, and platform selection recommendations for different research objectives. Instrument-level reporter readout context for TMT quantification is summarized in Mass Spectrometry TMT Technology.

Performance Characteristics of Mainstream TMT Quantification Platforms

The principal mass spectrometry platforms currently used for TMT quantification include the Orbitrap Fusion Lumos, Orbitrap Eclipse Tribrid, Exploris 480, and Orbitrap Ascend. The Orbitrap Fusion Lumos offers high resolution and a moderate scan rate, supports TMT 11-plex and 16-plex workflows, and is well-suited for basic research and post-translational modification analyses. Building on this foundation, the Orbitrap Eclipse enhances both scan speed and quantitative performance, supporting TMTpro 18-plex labeling, making it particularly suitable for complex samples and large-scale cohort studies. The Exploris 480, while exhibiting slightly lower resolution than the aforementioned platforms, features high scan efficiency and excellent stability, making it an ideal choice for high-throughput screening experiments. The latest Orbitrap Ascend platform provides further improvements in resolution, acquisition speed, and dynamic range, with systematic optimization for TMT quantification, particularly advantageous for frontier projects requiring exceptionally high throughput and ultra-deep proteome coverage. Some laboratories are also investigating the integration of timsTOF Pro with TMT-based workflows; however, as this instrument does not natively support isotope labeling quantification, specialized optimization of pre-processing and analysis workflows is required, and such applications are best conducted under the guidance of experienced service providers.

Figure 1. Mainstream TMT platforms differ in plex support, scan performance, and suitability for PTM work, high-throughput screening, or deep cohort proteomics.

Key Factors Influencing TMT Quantification Outcomes

In addition to the specifications of the mass spectrometry platform, TMT quantification performance is shaped by a combination of factors, including sample preparation, label purity, reaction efficiency, and data analysis strategies.

1. Critical Standardization of Sample Preparation Workflows

TMT quantification requires extremely high consistency across samples; even minor deviations can be magnified during signal acquisition, adversely affecting final quantitative results. Accurate protein concentration determination using the bicinchoninic acid (BCA) assay is recommended, along with strict consistency in digestion and labeling reaction times.

2. Rigorously Controlled Label Purity and Balanced Sample Loading

Mass spectrometry–grade, high-purity TMT reagents should be used to ensure consistent labeling efficiency across all channels. The use of high-precision sample loading systems can minimize cross-channel contamination and inter-batch bias.

During data analysis, platform-specific software such as Proteome Discoverer, MaxQuant, or Spectronaut should be selected, and combined with batch effect correction approaches (e.g., normalization, batch correction) to enhance the accuracy and comparability of quantitative results.

Figure 2. Beyond instrument choice, TMT outcomes depend on standardized preparation, controlled labeling and loading, and appropriate analysis with batch correction.

Prep and design controls that affect usable TMT ratios are discussed further in How to Optimize Proteomics TMT Experimental Design and Sample Prep.

TMT Quantification Platform Selection Recommendations for Different Research Objectives

The optimal TMT platform depends on the required depth of quantification, throughput, and data stability, which vary according to research objectives. For studies focusing on tumor biomarker discovery, the Orbitrap Eclipse or Orbitrap Ascend platforms are recommended, coupled with high-throughput 18-plex TMT workflows and multi-dimensional fractionation to maximize sensitivity and proteome coverage. For drug mechanism investigations, the Orbitrap Fusion Lumos or Exploris 480 can be combined with medium-throughput 11-plex workflows to achieve a balance between analytical efficiency and cost.

When research involves integrative modeling with transcriptomic, metabolomic, or other omics data, the Orbitrap Eclipse is particularly advantageous due to its robust stability and consistent data output, making it well-suited for multi-omics integration. For single-cell or low-input samples, TMT-Boost or nanoliter-scale quantification strategies are recommended to maximize detection sensitivity.

Figure 3. Platform selection for TMT quantification should align study goals with plex size, depth needs, and sample input constraints.

Advantages of MtoZ Biolabs’ TMT Quantification Services

MtoZ Biolabs offers a comprehensive, fully integrated TMT quantification solution encompassing five core modules: sample processing, TMT labeling, high-resolution mass spectrometry acquisition, bioinformatics analysis, and biological interpretation.

Our capabilities include:

• A range of high-end mass spectrometry platforms, including Orbitrap Eclipse, Fusion Lumos, and Exploris 480, to address diverse requirements for throughput and depth.
• Automated protein handling systems to ensure standardized experimental workflows and high reproducibility.
• Dual quality control measures for label purity and sample loading balance significantly improve data consistency.

In addition, our specialized bioinformatics team delivers advanced services, from interpreting protein quantification results and performing pathway enrichment analyses to building integrated multi-omics models, enabling clients to extract meaningful biological insights efficiently.

TMT-based quantification has become an indispensable tool in modern proteomics. Differences among platforms in resolution, throughput, sensitivity, and stability directly influence their suitability for specific research applications. Selecting an appropriate platform requires careful alignment of project goals, sample characteristics, and budget. Leveraging its advanced mass spectrometry infrastructure, standardized workflows, and experienced scientific team, MtoZ Biolabs is committed to delivering high-quality, customized TMT quantification services. Beyond ensuring data accuracy, we place strong emphasis on extracting and interpreting the underlying biological significance, supporting the progression of research from data generation to scientific discovery and ultimately to impactful breakthroughs. Researchers can also review the MtoZ Biolabs TMT Quantitative Proteomics Analysis Service for project-specific platform matching, plex planning, and TMT workflow support.